Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Booking Holdings Unveils Booking Partner Division to Accelerate B2B Travel Innovation

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026
    Facebook X (Twitter) Instagram
    Tanta TimesTanta Times
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Tanta TimesTanta Times
    Home » FDA flags child-friendly 7-OH kratom products as risky trend
    Health

    FDA flags child-friendly 7-OH kratom products as risky trend

    July 30, 2025
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    The U.S. Food and Drug Administration (FDA) is calling for tighter federal control over 7-hydroxymitragynine (7-OH), a potent psychoactive compound derived from the kratom plant, citing its high potential for abuse and opioid-like effects. The agency has formally recommended classifying 7-OH as a Schedule I controlled substance, aligning it with drugs such as heroin and cocaine under the Controlled Substances Act.

    The move follows a surge in the popularity of 7-OH products sold in vape shops, gas stations, and online retailers. While kratom in its natural form has long been used as a stimulant or pain reliever, 7-OH appears in much higher concentrations in processed products such as tablets, gummies, drink powders, and oral shots.

    These products are often marketed without regulatory approval, and some are packaged in formats like fruit-flavored edibles that may appeal to children, prompting further concern among health authorities. FDA Commissioner Dr. Marty Makary stated that 7-OH binds to the brain’s opioid receptors, potentially triggering respiratory depression, physical dependence, and withdrawal symptoms similar to those caused by prescription opioids.

    Growing public health concerns over synthetic kratom derivatives

    The compound has been shown to be more potent than morphine in animal models, raising alarms over its uncontrolled availability. The FDA emphasized that it has not approved any drug or dietary supplement containing kratom, 7-OH, or mitragynine, the plant’s other primary alkaloid.

    Health and Human Services Secretary Robert F. Kennedy Jr. called the recommendation part of a broader strategy to reduce opioid misuse. “We’re taking action on 7-OH as a critical step in the fight against opioid addiction,” Kennedy said during a press briefing. He underscored the need to prevent unregulated psychoactive compounds from contributing to another addiction crisis, particularly among youth.

    The FDA’s recommendation follows an earlier enforcement effort in which it issued warning letters to seven companies for the illegal marketing of 7-OH products. These companies were cited for distributing unapproved drug products, which the agency determined were neither safe nor effective for any medical use.

    Under current law, the Drug Enforcement Administration (DEA) will review the FDA’s request and conduct its own scheduling process, which includes rulemaking and public comment. According to the Legislative Analysis and Public Policy Association, kratom’s legal status varies by state.

    FDA cites urgent need for public education and regulation

    As of March 2025, seven states and the District of Columbia classify kratom as a controlled substance, while 18 others regulate its sale or possession. The remaining 26 states do not have specific restrictions. The FDA clarified that its latest action targets 7-OH specifically and does not apply to kratom leaf products in general, though those too have been linked to adverse outcomes, including fatalities.

    Researchers continue to study 7-OH’s health effects and potential risks. Dr. Kirsten Elin Smith of Johns Hopkins University, who is surveying users of the compound, noted that while some individuals report benefits such as pain relief or mood improvement, others experience strong addictive effects.

    Smith said more scientific data is necessary to fully understand the substance’s safety profile. The FDA warns that consumers using 7-OH products are exposed to substances with no proven safety or therapeutic value. As the agency advances its regulatory actions, it aims to close the gap between rapid market proliferation and public health oversight. – By Content Syndication Services.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026
    Editor's Pick

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026

    Sheikh Mohamed receives Venezuela’s Delcy Rodríguez in Abu Dhabi

    November 17, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026
    © 2026 Tanta Times | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.